GlassScriptPhysician profile
James Foster Beck
NPI 1114955085
$1,546.90
in general payments reported to CMS, 2019-2025
26 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $92.67 · 2021: $28.48 · 2022: $166 · 2023: $97.32 · 2024: $60.24 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $323.56 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $227.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $136.76 | 2019-2021 | |
| Astellas Pharma US INC | $108.68 | 2022-2024 | Padcev |
| Janssen Biotech, INC. | $99.47 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.58 | 2019-2020 | |
| Abbvie INC. | $89.74 | 2019-2025 | |
| Amgen INC. | $58.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $54.73 | 2019 | |
| Puma Biotechnology, INC. | $39.53 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.87 | 2020-2023 | Gilotrif |
| Merck Sharp & Dohme LLC | $35.00 | 2019 | |
| Recordati_rare_diseases_inc. | $30.03 | 2025 | Enjaymo |
| Pharmacyclics LLC, An Abbvie Company | $22.55 | 2019 | |
| Tactile Systems Technology INC | $22.07 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.72 | 2019 | |
| Foundation Medicine, INC. | $19.67 | 2019 | |
| Rigel Pharmaceuticals, INC. | $19.59 | 2019 | |
| Kyowa Kirin, INC. | $15.98 | 2019 | |
| Pfizer INC. | $15.65 | 2019 | |
| Incyte Corporation | $15.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.72 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.39 | 2019 | |
| Taiho Oncology, INC. | $11.44 | 2019 | |
| Phadia US INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.